Evidence map›Paper›PMID 42664178›Full record

ArticleAmerican journal of nephrology2026

Risks of Major Adverse Kidney Events in Non-Hispanic Black Patients with Diabetes or Hypertension: A Real-World Cohort Study.

Kiara N Mayhand, Anna Zemke, Radica Z Alicic, Lindsey M Kornowske, Cami R Jones, Kenn B Daratha, Christina L Reynolds, Susanne B Nicholas, Roland J Thorpe, Panayiotis Petousis and 4 more

Abstract read
In one paragraph

Article in American journal of nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kiara N MayhandJohns Hopkins Bloomberg School of Public Health, Baltimore, USA, kmayhan1@alumni.jh.edu.
Anna ZemkeProvidence Health and Service - Washington, Seattle, USA.
Radica Z AlicicProvidence Health and Service - Washington, Seattle, USA.
Lindsey M KornowskeProvidence Health and Service - Washington, Seattle, USA.
Cami R JonesProvidence Health and Service - Washington, Seattle, USA.
Kenn B DarathaProvidence Health and Service - Washington, Seattle, USA.
Christina L ReynoldsProvidence Health and Service - Washington, Seattle, USA.
Susanne B NicholasDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA, sunicholas@mednet.ucla.edu.
Roland J ThorpeJohns Hopkins Bloomberg School of Public Health, Baltimore, USA.
Panayiotis PetousisDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
Leonid ShpanerDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
Joshua J NeumillerCollege of Pharmacy and Pharmaceutical Sciences, Washington State University, Pullman, USA.
Keith C NorrisDavid Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
Katherine R TuttleProvidence Health and Service - Washington, Seattle, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionChronic kidney disease (CKD) disproportionately burdens non-Hispanic Black (NHB) patients who experience a three- to four-fold higher risk of kidney failure than non-Hispanic White (NHW) individuals. Diabetes and hypertension are the leading causes of CKD, yet the influence of race, social context, and clinical factors on major adverse kidney events (MAKEs) remains inadequately understood. This study examined relationships between race, social factors, and MAKE among patients with diabetes or hypertension.

methodsElectronic health record data from the CURE-CKD Registry (2013-2022) were used to assemble two mutually exclusive cohorts of NHB and NHW (reference) adults with (1) diabetes (N = 375,605) or (2) hypertension without diabetes (N = 710,768). The primary outcome was time to first MAKE, defined as ≥40% decline in estimated glomerular filtration rate (eGFR), eGFR <15 mL/min/1.73 m2, kidney failure, dialysis, transplant, or death. Cox proportional hazards models estimated associations between predictors and MAKE. Extreme gradient boosting (XGBoost) machine learning (ML) models were used as a complement to the traditional survival models to evaluate variable relationships with MAKE and compare predictive performance.

resultsNHB patients were younger (diabetes: 56 ± 15 vs. 62 ± 14 years; hypertension: 50 ± 16 vs. 59 ± 16 years), had more prevalent CKD (diabetes: 19% vs. 15%; hypertension: 8% vs. 7%), and had higher adjusted MAKE risk than NHW patients (diabetes: HR = 1.07, 95% CI: 1.04-1.11; hypertension: HR = 1.10, 95% CI: 1.06-1.14). MAKE occurred in 24% (n = 90,910) of the diabetes population over a median (interquartile range) of 4.1 (2.0-6.3) years, and 15% (n = 106,209) of the hypertension population over 4.4 (2.4-6.3) years. Non-commercial insurance (Medicaid, Medicare, or unclassified insurance [reference: Commercial]), higher social vulnerability index, more frequent hospitalizations, and urban residence were the top predictors of MAKE. XGBoost outperformed Cox models for MAKE prediction and SHapley Additive exPlanations value rankings confirmed key predictors identified in Cox models.

conclusionAcross two large cohorts for CKD, NHB patients experienced higher MAKE risk, shaped by neighborhood social and structural conditions rather than demographic and clinical characteristics alone. Integrating social risk assessment, improving guideline-directed testing, and using complementary ML and Cox modeling approaches may enhance early identification of CKD risk, support targeted intervention, and reduce disparities in CKD outcomes.

Indexed as

Diabetic kidney diseaseHypertensive kidney diseaseKidney failureMachine learningSocial health factors

Identifiers

PMID42664178
PMCPMC13688366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.